

Electronic Acknowledgement Receipt

EFS ID:	4041437		
Application Number:	10663431		
International Application Number:			
Confirmation Number:	2348		
Title of Invention:	Novel therapeutic targets in cancer		
First Named Inventor/Applicant Name:	David W. Morris		
Correspondence Address:	Lisa E. Alexander Sagres Discovery, Inc. c/o Chiron Corporation P.O. Box 8097 Emeryville CA 94662-8097 US 5109232585 -		
Filer:	Monica McCormick Graham/Lisa Becker		
Filer Authorized By:	Monica McCormick Graham		
Attorney Docket Number:	PP023357.0001 /20366-0710		
Receipt Date:	01-OCT-2008		
Filing Date:	15-SEP-2003		
Time Stamp:	14:13:29		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment	no
File Listing:	

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	NPL Documents	JollyEtAl.pdf	2983255 5bcf43f234586e03bb27a4225766c764ace1 936c	no	14
Warnings:					
Information:					
2	NPL Documents	JonesEtAl.pdf	892802 502fa10a10c2856668fa77e37b62ce69d045 cc41	no	4
Warnings:					
Information:					
3	NPL Documents	JoostenEtAl.pdf	932441 0ccaa3705f904c2913fed05c3bd4b2f9909b cfac	no	11
Warnings:					
Information:					
4	NPL Documents	JungEtAl.pdf	436767 353f50f26006e6c93c3964407d2285494158 d42f	no	10
Warnings:					
Information:					
5	NPL Documents	KabatEtAl.pdf	476490 d22dcfb44e43b969d91373e5a8b192c4de0 ac02b	no	11
Warnings:					
Information:					
6	NPL Documents	KaplittEtAl.pdf	1087297 c0e1ff7b359c7f8b5c10b112d55c8d35c346 cb93	no	7
Warnings:					
Information:					
7	NPL Documents	KarlinEtAl.pdf	465004 dc97e7d810ef971ab603989d5bdbd54734 11040f	no	5
Warnings:					
Information:					
8	NPL Documents	KeownEtAl.pdf	752507 aac1ac1972464f58fc65f0af7809c77f072b de0	no	7
Warnings:					
Information:					
9	NPL Documents	KettleboroughEtAl.pdf	1409559 1e043de87fa727cba3a5093c533429228c3 95649	no	11

Warnings:					
Information:					
10	NPL Documents	KimuraEtAl.pdf	1024593 a8b27404dc7cda44b05ebde0a2e8a2e1b4 6cf658	no	8
Warnings:					
Information:					
11	NPL Documents	KohlerEtAl.pdf	859720 8ed244467bdb1b8366ef735a3c772ec1fd 2bada	no	3
Warnings:					
Information:					
12	NPL Documents	KyteEtAl.pdf	7855382 6838c18b05f182836cbf543f76ef3c453733 b6e5	no	28
Warnings:					
Information:					
13	NPL Documents	LeeEtAlExpressionOfSmall.pdf	836487 b5d9bed3d7bab90f1ca8e11ffd29ac6cdbe 773f9	no	6
Warnings:					
Information:					
14	NPL Documents	LetsingerEtAlCationicOligonucleotides.pdf	188542 21a3968764c2028e2b2930e6f1d0e853d6e 382ed	no	2
Warnings:					
Information:					
15	NPL Documents	LetsingerEtAlEffectsPendantGroups.pdf	527267 7abd71ee412b43ddcb5b22ff4e4b2e45c cf294	no	7
Warnings:					
Information:					
16	NPL Documents	LetsingerEtAlPhosphoramidateAnalogs.pdf	343294 b808ffc620aab26abfdb417c9716b02a79c 5d85	no	4
Warnings:					
Information:					
17	NPL Documents	LiEtAlLeukaemiaDiseaseGenes.pdf	558421 2e992eac0a5a758612e1a2ca6928fb37799c 3a05	no	6
Warnings:					
Information:					
18	NPL Documents	LoBuglioEtAl.pdf	725480 bcbb085a2b57b2ea53da97081a98bbdd9e de49b9	no	5

Warnings:					
Information:					
19	NPL Documents	LockhartEtAl.pdf	1163363 f5b121ae6618d23b117795dee96a066a4d5 81618	no	6
Warnings:					
Information:					
20	NPL Documents	LonbergEtAl.pdf	1743194 b6b3931701f57626321decd934cd5941a4d b3cd7	no	15
Warnings:					
Information:					
21	NPL Documents	LonbergEtAlAntigenSpecific. pdf	534402 a53392afb8d004c408ce627892aee0afb086 2696	no	4
Warnings:					
Information:					
22	NPL Documents	LuoEtAl.pdf	936093 7a5e4d1cc22ef31b206a3f7c2ec9111d238f d728	no	6
Warnings:					
Information:					
23	NPL Documents	Lutz-FreyermuthEtAl.pdf	1125287 c63ea2798f7022b7fb/bba932a5132b82dd c95e4	no	5
Warnings:					
Information:					
24	NPL Documents	MagEtAl.pdf	530952 f73ef204f9b55e0f6297b02c3966d4cef3b61 dc7	no	5
Warnings:					
Information:					
25	NPL Documents	MarksEtAlANovelAnti- Seminoma.pdf	550785 954341a3644ed2327cec3f61d907ebd7459 d8774	no	5
Warnings:					
Information:					
26	NPL Documents	MarksEtAlBy-PassingHuman. pdf	1677405 ae3ffe1cb7e705bea0fcc4c6430cfdf9de871c 6ef	no	17
Warnings:					
Information:					
27	NPL Documents	MarksEtAlBy- PassingImmunization.pdf	732854 8c0b0cfb1dda08358c99bba9e3b9ff9c6803 1a480	no	5

Warnings:					
Information:					
28	NPL Documents	MarshallEtAl.pdf	1991765 b8afe3c90da886e436093b4f204486063b8 7fd3d	no	14
Warnings:					
Information:					
29	NPL Documents	MartinEtAl.pdf	413335 be587815f6df5b4217b79b33406a51b288c d7517	no	3
Warnings:					
Information:					
30	NPL Documents	MaskosEtAl.pdf	780802 00f36885c0634b735146663862ec92db253 19ee0	no	6
Warnings:					
Information:					
31	NPL Documents	MasuiEtAl.pdf	681771 f3bc70e0d9a75e1a295a8ca525aeeccce295 3e39	no	6
Warnings:					
Information:					
32	NPL Documents	MatherEtAl.pdf	657402 e794dcfc28516b8468ac69713f3932d9e96c 4685	no	6
Warnings:					
Information:					
33	NPL Documents	MeierEtAl.pdf	372176 db6eb01dbd881ba69a1ba394f220930930 925b6e	no	3
Warnings:					
Information:					
34	NPL Documents	Merrifield.pdf	1039835 010448e2185e5d78723dd996bc99fd4647 79efb	no	6
Warnings:					
Information:					
35	NPL Documents	MesmaekerEtAlComparisonOfRigid.pdf	421411 e93b6299fb4aeed5b7065764e0feb0ccf02d 172d	no	4
Warnings:					
Information:					
36	NPL Documents	MiuraEtAl.pdf	747495 a4c57e930eb15bc21067b690b6b6db783f0 2345f	no	6

Warnings:					
Information:					
37	NPL Documents	MiyagishiEtAl.pdf	718094 daad9323240e2a4fc2f88ca001fba74c7fc49 3cb	no	4
Warnings:					
Information:					
38	NPL Documents	MorrisonEtAlChimericHuman.pdf	526794 4d92f674a7ea5ff53b6b890eb2e88d4a9f1c 484c	no	5
Warnings:					
Information:					
39	NPL Documents	MorrisonEtAlGeneticallyEngineered.pdf	1781606 41251267cdae04f3207d808d92b7d781beb 39037	no	15
Warnings:					
Information:					
40	NPL Documents	MorrisonSuccessInSpecification.pdf	549968 4536dca5e793a12552a0c0bf54c3d5fa1599 92a1	no	2
Warnings:					
Information:					
41	NPL Documents	Mukhopadhyay.pdf	3851258 ae962a3a62ec66ac859f1ec3b788e119b9 15319	no	41
Warnings:					
Information:					
42	NPL Documents	MullisEtAl.pdf	1340879 b67a9a83376e8aff7a8ce04f64270c756bd4 269a	no	10
Warnings:					
Information:					
43	NPL Documents	NeedlemanEtAl.pdf	630999 048f0bd273057c9ee43618021f8c1cd769c0 d11e	no	6
Warnings:					
Information:					
44	NPL Documents	Neuberger.pdf	230286 8b90b012e9b743be1692d87b69dcdd66100 6d8ac0	no	1
Warnings:					
Information:					
45	NPL Documents	NevilleEtAl.pdf	804199 e787fc1cedd23bb8a9f4cd03c4ef47f507b 1dca	no	8

Warnings:					
Information:					
46	NPL Documents	NielsenApplicationsPeptide.pdf	454592 e4ae08758466ed1a986cc4083b5a464a3f5 aa50d	no	5
Warnings:					
Information:					
47	NPL Documents	NielsenEtAlSequenceSelective.pdf	780588 4d4fcdb3d0d14306390624433fea45378 dfa0	no	4
Warnings:					
Information:					
48	NPL Documents	Nygren.pdf	764142 91df98759d69cfdd78782938a61c265d9df0 c221	no	6
Warnings:					
Information:					
49	NPL Documents	Olsen.pdf	1539540 405aa216543097c9d6d06c87490443c91ce c35e1	no	9
Warnings:					
Information:					
50	NPL Documents	PaborskyEtAl.pdf	754764 2ce9131ced938f90abb5e3b50718206f542 bc9dd	no	7
Warnings:					
Information:					
51	NPL Documents	PadlanAnatomyOfTheAntibody.pdf	4071993 afdb5228d6d231adc46321b597629d805b d8c03	no	49
Warnings:					
Information:					
52	NPL Documents	PadlanAPossibleProcedure.pdf	1004300 6aba86a1dc93e3fe0b55b0111f5f9577cbd9 f432	no	10
Warnings:					
Information:					
53	NPL Documents	PainEtAl.pdf	634380 280e64f4bbd4439749c6b64d3f1f79a8f7b1 e763	no	7
Warnings:					
Information:					
54	NPL Documents	PatanjaliEtAl.pdf	659552 8b702d6dafa6d073135accd2b70813e6003 5f8af	no	5

Warnings:					
Information:					
55	NPL Documents	PauleEtAITranscriptionByRNA.pdf	1829008 59a1acc515d0a65ef0546735855323bb630 d8ccc	no	16
Warnings:					
Information:					
56	NPL Documents	PaulEtAIEffectiveExpression.pdf	723047 b78f92da35f1476198782b168730bec6ba1 75685	no	4
Warnings:					
Information:					
57	NPL Documents	PauwelsEtAl.pdf	471224 4a1a61d001416dda689f3f22ed58c5bd22b fd891	no	5
Warnings:					
Information:					
58	NPL Documents	PearsonEtAl.pdf	812399 812d53fd9d68b09b50cd79a58a7b7972639 f554d	no	5
Warnings:					
Information:					
59	NPL Documents	PeaseEtAl.pdf	483487 b39e5f0364bd2be50da5a9e69f910adff5867 5618	no	5
Warnings:					
Information:					
60	NPL Documents	Pevzner1-TupleDNA.pdf	1706907 765bd4f1f8c8166ab64b17f1871aaefdf5d49 512b	no	11
Warnings:					
Information:					
Total Files Size (in bytes):				65579641	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.